image
Healthcare - Biotechnology - NASDAQ - US
$ 3.25
-1.19 %
$ 48.8 M
Market Cap
-0.63
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one JSPR stock under the worst case scenario is HIDDEN Compared to the current market price of 3.25 USD, Jasper Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one JSPR stock under the base case scenario is HIDDEN Compared to the current market price of 3.25 USD, Jasper Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one JSPR stock under the best case scenario is HIDDEN Compared to the current market price of 3.25 USD, Jasper Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart JSPR

image
$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
0 REVENUE
0.00%
-76.2 M OPERATING INCOME
-10.71%
-71.3 M NET INCOME
-10.55%
-62.6 M OPERATING CASH FLOW
-20.23%
-532 K INVESTING CASH FLOW
-99.25%
47.9 M FINANCING CASH FLOW
-52.58%
0 REVENUE
0.00%
-21.8 M OPERATING INCOME
13.77%
-21.2 M NET INCOME
12.66%
-22.8 M OPERATING CASH FLOW
-8.08%
4 K INVESTING CASH FLOW
105.26%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Jasper Therapeutics, Inc.
image
Current Assets 75.8 M
Cash & Short-Term Investments 71.6 M
Receivables 0
Other Current Assets 4.17 M
Non-Current Assets 4.09 M
Long-Term Investments 0
PP&E 2.85 M
Other Non-Current Assets 1.24 M
89.66 %5.22 %3.57 %Total Assets$79.9m
Current Liabilities 15.2 M
Accounts Payable 4.03 M
Short-Term Debt 1.09 M
Other Current Liabilities 10.1 M
Non-Current Liabilities 2.99 M
Long-Term Debt 0
Other Non-Current Liabilities 2.99 M
22.10 %5.98 %55.53 %16.40 %Total Liabilities$18.2m
EFFICIENCY
Earnings Waterfall Jasper Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 76.2 M
Operating Income -76.2 M
Other Expenses -4.97 M
Net Income -71.3 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)000(76m)(76m)5m(71m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-115.56% ROE
-115.56%
-89.20% ROA
-89.20%
-113.57% ROIC
-113.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Jasper Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)202020202021202120222022202320232024202420252025
Net Income -71.3 M
Depreciation & Amortization 1.37 M
Capital Expenditures -552 K
Stock-Based Compensation 6.62 M
Change in Working Capital 173 K
Others 797 K
Free Cash Flow -63.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Jasper Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for JSPR of $51.1 , with forecasts ranging from a low of $6 to a high of $65 .
JSPR Lowest Price Target Wall Street Target
6 USD 84.62%
JSPR Average Price Target Wall Street Target
51.1 USD 1473.63%
JSPR Highest Price Target Wall Street Target
65 USD 1900.00%
Price
Max Price Target
Min Price Target
Average Price Target
707060605050404030302020101000Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Jasper Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
19.9 K USD 1
9-12 MONTHS
19.1 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)---- $JSPR--JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm. businesswire.com - 2 weeks ago
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway Jasper Therapeutics, Inc. announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. Jasper has refined its operating plan to focus on its briquilimab programs in chronic urticaria, and as a result has executed a workforce reduction of approximately 50% of its current employees. In order to focus on developing briquilimab in chronic urticaria and completing the BEACON, SPOTLIGHT and open label extension studies, Jasper is halting its other clinical and preclinical programs, including the ETESIAN study in asthma, the SCID study and the ongoing investigator-sponsored studies.Jasper no longer plans to initiate additional mast cell focused clinical development program this year. https://www.marketscreener.com - 2 weeks ago
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. globenewswire.com - 2 weeks ago
Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem Jasper Therapeutics, Inc. JSPR stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga Pro. benzinga.com - 2 weeks ago
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria 8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts appear to be confounded by issues with one drug product lot ETESIAN study in asthma to be stopped due to same drug product lot issue No grade 3 or higher treatment related adverse events reported Company to host conference call and webinar today, Monday, July 7, at 8:30 a.m. EDT REDWOOD CITY, Calif. globenewswire.com - 2 weeks ago
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria 11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif. globenewswire.com - 1 month ago
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in cold urticaria (ColdU) or symptomatic dermographism (SD) during an oral session on Saturday, June 14. globenewswire.com - 1 month ago
Jasper Therapeutics to Present at Upcoming Investor Conferences REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences: globenewswire.com - 2 months ago
8. Profile Summary

Jasper Therapeutics, Inc. JSPR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 48.8 M
Dividend Yield 0.00%
Description Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Contact 2200 Bridge Pkwy, Redwood City, CA, 94065 https://jaspertherapeutics.com
IPO Date Jan. 10, 2020
Employees 64
Officers Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research & Translational Medicine Ms. Kimberly Baxter Vice President & Head of Quality Mr. Jeetinder Singh Mahal M.B.A. Chief Operating Officer Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer Mr. Ronald A. Martell President, Chief Executive Officer & Director Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Member of Scientific Advisory Board & Director Mr. Matthew Ford Senior Vice President of Human Resources Ms. Patricia Carlos Senior Vice President of Regulatory Affairs & Quality Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations Mr. David Ku M.D. Vice President of Corporate Development, Portfolio Strategy & Management